证券之星消息，截至2025年12月25日收盘，开立医疗(300633)报收于26.75元，上涨0.34%，换手率 0.76%，成交量3.28万手，成交额8763.77万元。 该股主要指标及行业内排名如下： 12月25日的资金流向数据方面，主力资金净流出740.52万元，占总成交额8.45%，游资资金净流入77.14 万元，占总成交额0.88%，散户资金净流入663.39万元，占总成交额7.57%。 近5日资金流向一览见下表： 开立医疗2025年三季报显示，前三季度公司主营收入14.59亿元，同比上升4.37%；归母净利润3351.11 万元，同比下降69.25%；扣非净利润2399.1万元，同比下降72.14%；其中2025年第三季度，公司单季度 主营收入4.95亿元，同比上升28.42%；单季度归母净利润-1351.92万元，同比上升78.05%；单季度扣非 净利润-1588.57万元，同比上升76.92%；负债率24.22%，投资收益207.82万元，财务费用-3830.36万 元，毛利率60.36%。开立医疗（300633）主营业务：医疗诊断及治疗设备的自主研发、生产与销售。 该股最近90天内共有13家 ...

证券之星消息，截至2025年12月24日收盘，开立医疗(300633)报收于26.66元，上涨1.41%，换手率 0.55%，成交量2.37万手，成交额6315.8万元。 12月24日的资金流向数据方面，主力资金净流出606.3万元，占总成交额9.6%，游资资金净流出575.43 万元，占总成交额9.11%，散户资金净流入1181.73万元，占总成交额18.71%。 近5日资金流向一览见下表： 该股主要指标及行业内排名如下： 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 开立医疗2025年三季报显示，前三季度公司主营收入14.59亿元，同比上升4.37%；归母净利润3351.11 万元，同比下降69.25%；扣非净利润2399.1万元，同比下降72.14%；其中2025年第三季度，公司单季度 主营收入4.95亿元，同比上升28.42%；单季度归母净利润-1351.92万元，同比上升78.05%；单季度扣非 净利润-1588.57万元，同比上升76.92%；负债率24.22%，投资收益207.82万元，财务费用-3830.36万 元 ...

每经AI快讯，有投资者在投资者互动平台提问：董秘你好，请问贵司新业务IVUS 导管耗材和硬镜设备 是否导入顺利？ （记者 张明双） 开立医疗（300633.SZ）12月24日在投资者互动平台表示，公司微创外科、心血管介入业务发展顺利， 近两年均取得较高增速。 ...

Group 1 - The core viewpoint of the article is that the company, KaiLi Medical, has experienced significant growth in its minimally invasive surgery and cardiovascular intervention businesses over the past two years [1] Group 2 - The company reported that both business segments have achieved high growth rates [1]

该股主要指标及行业内排名如下： | 指标 | 开立医疗 | 医疗器械行业均值 | 行业排名 | | --- | --- | --- | --- | | 总市值 | 113.76亿元 | 107.86亿元 | 27 125 | | 净资产 | 31.19亿元 | 38.83亿元 | 46 125 | | 净利润 | 3351.11万元 | 2.1亿元 | 75 125 | | 市盈率(动) | 254.6 | 78.7 | 88 125 | | 市净率 | 3.65 | 3.73 | 88 125 | | 毛利率 | 60.36% | 51.02% | 50 125 | | 净利率 | 2.3% | 9.59% | 89 125 | | ROE | 1.07% | 0.23% | 85 125 | 证券之星消息，截至2025年12月23日收盘，开立医疗(300633)报收于26.29元，下跌1.35%，换手率 0.54%，成交量2.35万手，成交额6213.08万元。 12月23日的资金流向数据方面，主力资金净流出369.65万元，占总成交额5.95%，游资资金净流出 170.45万元，占总成交额2.74%，散 ...

开立医疗2025年三季报显示，前三季度公司主营收入14.59亿元，同比上升4.37%；归母净利润3351.11 万元，同比下降69.25%；扣非净利润2399.1万元，同比下降72.14%；其中2025年第三季度，公司单季度 主营收入4.95亿元，同比上升28.42%；单季度归母净利润-1351.92万元，同比上升78.05%；单季度扣非 净利润-1588.57万元，同比上升76.92%；负债率24.22%，投资收益207.82万元，财务费用-3830.36万 元，毛利率60.36%。开立医疗（300633）主营业务：医疗诊断及治疗设备的自主研发、生产与销售。 证券之星消息，截至2025年12月22日收盘，开立医疗(300633)报收于26.65元，上涨0.26%，换手率 0.48%，成交量2.06万手，成交额5503.53万元。 12月22日的资金流向数据方面，主力资金净流出423.05万元，占总成交额7.69%，游资资金净流入78.72 万元，占总成交额1.43%，散户资金净流入344.32万元，占总成交额6.26%。 近5日资金流向一览见下表： 该股主要指标及行业内排名如下： 以上内容为证券之星据公开信 ...

Core Viewpoint - The official launch of the Hainan Free Trade Port on December 18 marks a significant milestone with the first batch of medical equipment undergoing bonded maintenance under the "executive exception measures" policy, indicating a breakthrough in the bonded maintenance industry for medical devices in Hainan [1] Group 1: Policy Implementation - The first batch of medical equipment parts, valued at 347,300 yuan, was imported by Kaili Biomedical Technology (Haikou) Co., Ltd. and successfully cleared customs [1] - The customs authorities provided comprehensive support throughout the process, from policy consultation to customs declaration guidance [1] - The bonded maintenance business will operate within the Haikou National High-tech Industrial Development Zone, catering to global after-sales needs for medical equipment, thus establishing a complete business chain of "global order, Hainan maintenance, global delivery" [1] Group 2: Customs Support and Collaboration - The Haikou Customs quickly coordinated with local departments to address challenges and facilitate the smooth execution of this representative business [2] - A one-on-one connection mechanism was established between customs officials and the enterprise to understand its business model and import plans, leading to tailored customs and regulatory solutions [2] - Customs officials acted as "policy advisors," assisting the company in navigating the complexities of the new policy and ensuring efficient completion of the declaration process [2] Group 3: Policy Benefits - The executive exception measures cover a wide range of products, enhancing service efficiency for enterprises and supporting industrial development [3] - The customs clearance process has been simplified, eliminating the need for import license verification and requiring only the selection of an additional product attribute code during declaration [3] - The new model achieves efficient regulation through a combination of automated system control and targeted manual checks, facilitating a seamless regulatory experience [3]

Core Viewpoint - The implementation of the "two ends outside" bonded maintenance policy in Hainan Free Trade Port allows for the repair of medical equipment, enhancing service efficiency and reducing costs for overseas clients [2][3]. Group 1: Policy Implementation - A batch of medical equipment parts, specifically endoscope components, has been approved for bonded maintenance under the new policy [2]. - The policy is part of the Ministry of Commerce's announcement regarding the Hainan Free Trade Port, which includes a list of goods allowed for "two ends outside" bonded maintenance [3]. Group 2: Company Overview - Kaili Biomedical Technology (Haikou) Co., Ltd., a subsidiary of Shenzhen Kaili Biomedical Technology Co., Ltd., is leading the initiative in the bonded maintenance of medical devices [2]. - Kaili Medical is recognized as a leading enterprise in the ultrasound and endoscope sectors, with products exported globally [2]. Group 3: Market Demand and Efficiency - The international market's demand for timely and professional equipment maintenance is increasing, prompting the need for efficient repair solutions [2]. - The establishment of a global repair center in Haikou allows for direct receipt of equipment from various regions, including the EU, US, and Middle East, significantly improving service response times and reducing maintenance costs [3].

12月18日的资金流向数据方面，主力资金净流出173.26万元，占总成交额3.05%，游资资金净流入 177.28万元，占总成交额3.12%，散户资金净流出4.03万元，占总成交额0.07%。 近5日资金流向一览见下表： | | | | | 日期 收盘价 涨跌幅 主力净流入 主力净占比 游资净点比 散户净流入 散户净占比 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 2025-12-18 | 26.67 | 0.19% | -173.26万 | -3.05% | 177.28万 | 3.12% | -4.03万 | -0.07% | | 2025-12-17 | 26.62 | 0.41% | -191.20万 | -3.51% | 84.91万 | 1.56% | 106.28万 | 1.95% | | 2025-12-16 | 26.51 | 0.11% | -11.16万 | -0.27% | 266.45万 | 6.38% | -255.28万 | -6.11% | | 2025-12-15 | 26.48 | ...

Investment Rating - The report maintains a "Positive" investment rating for the medical device industry [3]. Core Insights - The medical device industry is expected to return to positive growth in 2025 after two consecutive years of decline in 2023 and 2024, driven by increased demand for hospital equipment due to equipment renewal policies [10]. - Monthly procurement data shows a continuous recovery trend, with November 2025 procurement amounting to 208.76 billion yuan, reflecting a month-on-month increase of 26.93% [18]. - The domestic production rate of medical devices has increased from 19% in 2019 to 48% in November 2025, indicating a significant shift towards local manufacturing [21]. Summary by Sections Equipment Procurement - The medical device procurement is showing a sustained recovery, with a projected annual procurement scale for 2025 estimated between 1,884 billion yuan and 2,422 billion yuan based on the first half's performance [14]. - The procurement amount for November 2025 was 208.76 billion yuan, with a year-on-year decrease of 0.25% but a month-on-month increase of 26.93% [18]. Market Segmentation - The procurement scale for ultrasound devices in November 2025 reached 22.40 billion yuan, showing a year-on-year growth of 17.60% and a month-on-month growth of 41.67% [27]. - CT device procurement in November 2025 was 25.36 billion yuan, with a year-on-year increase of 27.58% and a month-on-month increase of 22.82% [28]. - MRI procurement in November 2025 was 23.94 billion yuan, reflecting a year-on-year growth of 5.68% and a month-on-month growth of 29.94% [31]. - Digestive endoscope procurement in November 2025 was 7.30 billion yuan, with a year-on-year increase of 3.26% and a month-on-month increase of 41% [36]. - Surgical robot procurement in November 2025 was 5.60 billion yuan, showing a year-on-year growth of 8.33% but a month-on-month decrease of 11.53% [37]. Company Performance - Mindray Medical's procurement in November 2025 was 13.18 billion yuan, with a year-on-year increase of 12.16% and a month-on-month increase of 38.34% [44]. - United Imaging's procurement in November 2025 reached 14.33 billion yuan, reflecting a year-on-year growth of 30.40% and a month-on-month growth of 31.15% [46]. - KAILI Medical's procurement in November 2025 was 2.47 billion yuan, with a year-on-year increase of 62.15% and a month-on-month increase of 17.95% [50]. - Aohua Endoscopy's procurement in November 2025 was 1.09 billion yuan, showing a year-on-year growth of 59.95% and a month-on-month growth of 62.14% [54].